Diferencia entre revisiones de «Uridine triacetate»
(Creation of page) |
Sin resumen de edición |
||
| Línea 1: | Línea 1: | ||
==Administration== | ==Administration== | ||
*Type: Antidote; Rescue Agent(Chemotherapy) | *Type: [[Antidote]]; Rescue Agent(Chemotherapy) | ||
*Dosage Forms: Granule 10g | *Dosage Forms: Granule 10g | ||
*Routes of Administration: Oral | *Routes of Administration: Oral | ||
| Línea 56: | Línea 56: | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Heme/Onc]] | |||
[[Category:Toxicology]] | |||
Revisión actual - 23:14 23 sep 2019
Administration
- Type: Antidote; Rescue Agent(Chemotherapy)
- Dosage Forms: Granule 10g
- Routes of Administration: Oral
- Common Trade Names: Vistogard
Adult Dosing
Fluorouracil or capecitabine toxicity
- 10g PO q6h x20 doses
- Give with soft food
Pediatric Dosing
Fluorouracil or capecitabine toxicity
- 1+ yr old
- 6.2 g/m^2 PO q6h x20 doses
- Give with soft food
- Max: 10g/dose
Special Populations
- Pregnancy Rating: C
- Lactation risk: Caution with use, weight risk/benefit
Renal Dosing
- Adult: Not defined
- Pediatric: Not defined
Hepatic Dosing
- Adult: Not defined
- Pediatric: Not defined
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- May occur, but none reported
Common
Pharmacology
- Half-life: 2-2.5 hrs
- Metabolism: Tissue, prodrug converted to uridine
- Excretion: Urine
Mechanism of Action
- Incorporates into RNA, inhibiting cell damage and death caused by fluoruracil or capecitabine